G1 THERAPEUTICS, INC.

(GTHX)
  Rapport
Temps Différé Nasdaq  -  18/05 22:00:01
4.630 USD    0.00%
05/05G1 THERAPEUTICS, INC. : Needham & Co. reste à l'achat
ZM
05/05G1 THERAPEUTICS, INC. : Wedbush réitère son opinion positive sur le titre
ZM
04/05Earnings Flash (GTHX) G1 THERAPEUTICS affiche un chiffre d'affaires de 6,9 millions de dollars au premier trimestre.
MT
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur G1 THERAPEUTICS, INC.
18/05G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conferenc..
04/05G1 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
04/05TRANSCRIPT : G1 Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
04/05Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q1 Revenue $6.9M
04/05Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q1 Loss $-1.15
04/05G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlight..
04/05G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
02/05G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/04G1 therapeutics to release first quarter 2022 financial results and provide business up..
21/04G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business U..
06/04G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
04/04G1 therapeutics announces inducement grants under nasdaq listing rule 5635(4)
01/04G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of M..
31/03G1 Therapeutics, Inc. Announces Results of A Retrospective
02/03G1 therapeutics announces inducement grants under nasdaq listing rule 5635(4)
01/03G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/03G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the ..
23/02G1 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
23/02TRANSCRIPT : G1 Therapeutics, Inc., Q4 2021 Earnings Call, Feb 23, 2022
23/02G1 Therapeutics Reports Wider Q4 Loss as Revenue Declines; Provides Guidance
23/02G1 THERAPEUTICS : Provides Fourth Quarter and Full Year 2021 Financial Results and Operati..
23/02G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
23/02Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $5.8M, vs. Street Est of $5.72..
23/02G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operat..
23/02NORTH AMERICAN MORNING BRIEFING : Stocks to -2-
09/02G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Busi..
02/02G1 therapeutics announces inducement grants under nasdaq listing rule 5635(4)
01/02G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/01TRANSCRIPT : G1 Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference,..
10/01G1 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
06/01INSIDER SELL : G1 Therapeutics
04/01G1 therapeutics announces inducement grants under nasdaq listing rule 5635(4)
04/01G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioCo..
03/01G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021G1 therapeutics announces expansion of cosela (trilaciclib) sales force
2021TRANSCRIPT : G1 Therapeutics, Inc. - Special Call
2021G1 THERAPEUTICS : Announces Expansion of COSELA™ (Trilaciclib) Sales Force - Form 8-K
2021G1 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Mater..
2021G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
2021G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
2021G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021G1 Therapeutics Initiates Phase 2 Trial to Further Study Trilaciclib in Tumor Microenvi..
2021G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (M..
2021G1 Therapeutics, Inc. Initiates Phase 2 Trial to Support Antitumor Mechanism of Action ..
2021G1 therapeutics announces initiation of new phase 2 trial of trilaciclib in combination..
2021China Accepts Simcere Pharma's Marketing Application for Lung Cancer Drug; Shares Jump ..
2021G1 Therapeutics Initiates Phase 2 Trial of Trilaciclib, Trodelvy Combination to Treat B..
2021G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination..
2021G1 Therapeutics, Inc. Announces Initiation of New Phase 2 Trial of Trilaciclib in Combi..
2021Immune analysis from phase 2 triple negative breast cancer trial demonstrates trilacicl..
2021Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilacicl..
2021G1 Therapeutics, Inc. Announces Results from an Immunologic Analysis of Phase 2 Study
2021G1 Therapeutics to Participate in Two Upcoming Conferences
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
2021G1 THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and ..
2021G1 Therapeutics Posts Wider Q3 Loss as Revenue Slumps
2021November 2021 Corporate Presentation
2021TRANSCRIPT : G1 Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021
2021G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlight..
2021G1 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operations ..
2021Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q3 Loss $-1.00, vs. Street Est of $-0.98
2021Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q3 Revenue $4.9M, vs. Street Est of $4.78..
2021G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlight..
2021G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021G1 THERAPEUTICS : to Provide Third Quarter 2021 Financial Results and Business Update on N..
2021G1 THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
2021G1 Therapeutics, Inc. Announces Resignation of Seth A. Rudnick from Board of Directors
2021G1 THERAPEUTICS : Retrospective analysis of pooled results from three studies shows cosela..
2021Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilac..
2021G1 Therapeutics, Inc. Announces Results from Retrospective Analysis of Pooled Results o..
2021G1 THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021G1 THERAPEUTICS : Announces Permanent J-Code from Centers for Medicare and Medicaid Servic..
2021NORTH AMERICAN MORNING BRIEFING : Fears Heighten -2-
2021G1 THERAPEUTICS : Announces new supplemental cosela (trilaciclib) sales force
1  2  3  4  5  6  7Suiv.
Prochain événement sur G1 THERAPEUTICS, INC.